Applied therapeutics announces positive data trend in at-007 action-galactosemia kids pediatric trial; trial will continue to 18 months in blinded format

• the study did not yet reach statistical significance at 12 months of treatment; however, at-007 (gavorostat) demonstrated a trend in clinical benefit vs. placebo • applied therapeutics plans to meet with the ema to discuss potential submission of the current data package for conditional approval in the eu • trial will continue to 18 months in blinded format
APLT Ratings Summary
APLT Quant Ranking